Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tumor antigen-sensitized dendritic cell vaccine (Sichuan University)
- Development stage
- Unknown
- Lead developer
- Sichuan University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This tumor antigen-sensitized dendritic cell (DC) vaccine is an autologous cell therapy developed by Sichuan University for the treatment of esophageal squamous cell carcinoma (ESCC). The vaccine is produced by harvesting a patient's own dendritic cells and sensitizing them with tumor-associated antigens (TAAs) derived from the patient's tumor tissue. Once re-administered to the patient via subcutaneous injection, these sensitized dendritic cells present the tumor antigens to the patient's T cells, thereby priming and activating a targeted immune response against residual cancer cells. It is primarily being investigated as a postoperative adjuvant therapy to prevent disease recurrence in patients with ESCC.
- Other names
- tumor antigen-sensitized dendritic cell vaccine-Sichuan University-esophageal squamous cell carcinomaTumor antigen-sensitized DC vaccineTumor antigen-sensitized DC vaccine (Sichuan University)
Beyond the preview
Go deeper on tumor antigen-sensitized dendritic cell vaccine (Sichuan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tumor antigen-sensitized dendritic cell vaccine (Sichuan University).